The 9MMInvasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market is expected to offer an $ opportunity of USD XX Million over the analysis period. Market was estimated USD XX Million during 2023 and expected to grow at a significant CAGR XX% over the projected period. And by the end of 2033, the market is expected to touch USD XX Million.
Invasive extraintestinal pathogenic E.coli (ExPEC) is the leading cause of UTIs infections, sepsis, and bacteremia especially in elderly patients. Invasive extraintestinal pathogenic E.coli is also considered as the leading cause of neonatal meningitis. Growing cases of antibiotic resistance, putting substantial burden on public health and economic. ExPEC strains are highly susceptible to multidrug resistance, implicating in surging huge number of hospitalizations and mortality. It is estimated that more than 10 million deaths will be caused by antimicrobial resistance (AMR) by 2050. Even now global health care bodies have raised serious concerns regarding antimicrobial resistance (AMR) across major markets.
Patients on antibiotics for a longer period, are more susceptible to get bacterial infections. Lack of substantial progress in the developments of novel antibiotics limiting treatment options. Thus, majority of the patients rely on already available antibiotics leading to large number of AMR case around the world. According to World bank estimates, AMR could result in approximately USD 1 trillion an additional healthcare cost burden by 2050, and US$ 1 trillion to US$ 3.4 trillion GDP losses per year by 2030
Report has Covered Granular-level Analysis in Each Mapped Market
Invasive extraintestinal pathogenic E.coli (ExPEC) disease Burden Analysis: (Result shown here is reflecting from studies meta-analysis, and CSP Analytics Solutions Analysis)
This section explored the epidemiology associated with Invasive extraintestinal pathogenic E.coli (ExPEC) disease
Extraintestinal pathogenic E. coli (ExPEC) causing XX million cases annually in the 9MM
XX million cases receiving treatment
Cases by causes type:
Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million urinary tract infections (UTIs) cases annually in 9MM
Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million bloodstream infections (BSIs) cases annually in 9MM
Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million meningitis cases annually in 9MM
Extraintestinal Pathogenic Escherichia coli (ExPEC) cause XX million pneumonia cases annually in 9MM
Number of cases prevalent, annually diagnosed cases
Treatment Landscape:
Treatment of invasive ExPEC disease requires holistic framework to address diverse set of patients accompanied with various therapeutic conditions (Co-morbidities). Collaboration among various specialties imperative to devise tailoring treatment plan. Efforts to promote antimicrobial stewardship and advocacy at patient and physician level is crucial approaches to mitigate the risk of antibiotic resistance in ExPEC strains.
Various treatment approaches involves while treating Invasive extraintestinal pathogenic E.coli (ExPEC) disease patients such as Antimicrobial Therapy, Surgical Intervention, Adjunctive Therapies, Follow-Up and Monitoring
Patients with co-morbidities and without co-morbidities are treated with different set of treatment. Specific treatment strategies tailored based on disease severity and co-morbid conditions
Report explored, treatment strategies for different set of patients. What are the approaches embraced by physicians, while treating patients with co-morbidities and without co-morbidities
Invasive extraintestinal pathogenic E.coli (ExPEC) disease market is struggling to get an effective treatment
High spectrum antibiotics is currently the mainstay of therapy for patients
Recent clinical guidelines enable the streamlining the treatment approaches
Report, investigated patient segment targeted by each therapy type:
Report has examined the how many and what type of cases refer to which type of therapy based on experts’ opinion analysis.
Report also examined Approaches for Management
First-line of therapy
Second-line of therapy
Drug
Targeted Patient Segment
Antimicrobial Therapy
XX
Supportive Care
XX
Surgical Intervention
XX
Adjunctive Therapies
XX
Follow-Up and Monitoring
XX
Targeted Respondents
Infectious Disease Specialists
XX
General Physician
XX
Urologists
XX
Surgeons
XX
Upcoming Therapy Assessment (Pipeline Analysis)
Report also provided promising therapy assessment including drugs, existing therapies, and upcoming therapy
Novel drug target assessment. For instance, development of vaccine-based therapy
Expected launch of key pipeline assets
Experts Opinion on the matter of accepting novel treatment options
Promising molecules advantages offer over existing therapy
Impact assessment of pipeline assets
Drug analogue analysis
Expected annual cost of therapy
Market Segmentation Analysis by:
By Infections Type
Urinary Tract Infection’s
Blood Stream Infection’s
Meningitis
Pneumonia
By Patient
Pediatric
Adult
Elderly
By Treatment Type
Antibiotics
Empirical therapy
Targeted therapy
Vaccines
By Gender
Female
Male
By Route of Administration
Oral
Injectable
By Line of Therapy
First-line of therapy
Second-line of therapy
Market Dynamics: Explored in the report
Untreated Prevalent Pool of Invasive extraintestinal pathogenic E.coli (ExPEC) disease
Huge medical unmet need
Lack of specific treatment
Market Challenges: Explored in the report
Inadequate efficacious treatment options
Treating AMR cases
Research gap
Cost of therapy
Treatment compliance and adherence
Mapped Geography: Nine Major Markets (9MM)
Report has fragmented the total market into five regions such as:
United States
5-Europe
Germany
France
Italy
Spain
United Kingdom
Rest of Europe
China
Japan
India
RoW (Rest of World)
Each mapped region has been examined at granular level based on below parameters:
United States Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
5-Europe Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
By Country
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
China Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
India Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Japan Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Rest of the World Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
Market Size and Forecast Model 2023-2033
Disease Overview
Current Treatment Approaches
Key Opinion Leader (KOL) Views
Disease Burden Analysis (Prevalence, Diagnosed, Treatable Prevalent Pool Analysis)
Diagnosis and Treatment Guidelines
Drug Share Analysis (%)
Drug Treatment Adherence and Compliance Rate (%)
Annual Cost of Therapy
Current Treatment Landscape and Upcoming therapy Assessment
Market Unmet Need Analysis
Key Players in the Market and their Market share (%)
Competitive Landscape (Existing and Pipeline Players):
Players in Market Space - Players explored in the report has been analyzed at various parameters. Analysis done around, product offerings, pipeline assets, In-licensing and out-licensing opportunities, financial health, market share, collaboration and partnership, patents, funding secures, technology outlook, future strategic move and investment.
Companies Profile:
Sanofi
J&J Pharmaceuticals
Forge Therapeutics
Tetraphase Pharmaceuticals
Entasis Therapeutics
Nabriva Therapeutics
Polyphor
Cidara Therapeutics
Iterum Therapeutics
Others
Reason to buy this report:
Fostering Understanding on Invasive extraintestinal pathogenic E.coli (ExPEC) disease Drug Treatment Market
In Order to Understand the Market Potential
Opportunity Analysis (exist in the market for players)